Market Access News | pharmaphorum

News

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.

News

NICE approves Bayer’s liver cancer drug

NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug.

News

Mundipharma's Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

Paid medicine. Cost of treatment. Isolated 3D image

New UK drug pricing deal promises faster medicines access

The UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the almost 60-year-old Pharmaceutical Price Regulation Scheme (PPRS).

News

Novartis/Spark's sight gene therapy approved in EU

Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.

Boehringer Ingelheim axes biosimilars development outside US

NICE approves Bayer’s liver cancer drug

Mundipharma's Neulasta biosimilar approved in EU

NHS saving £300m with Humira biosimilar deal

New UK drug pricing deal promises faster medicines access

Novartis/Spark's sight gene therapy approved in EU

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks